Colorectal cancer (CRC) remains a significant global health challenge, ranking third in incidence and second in mortality among cancers worldwide. This review addresses the complex landscape of CRC, focusing on incidence, mortality trends, preventive strategies, and the evolving therapeutic approaches, particularly highlighting the role of platinum-based drugs like oxaliplatin (OXP). It also underscores the increasing burden of CRC, with factors such as westernized diets, aging populations, and genetic predispositions contributing to its prevalence. Therapeutically, early detection greatly enhances survival rates, emphasizing the importance of regular colonoscopies and stool tests. For advanced CRC, chemotherapy remains pivotal, with OXP as a cornerstone treatment despite its associated chemotherapy-induced peripheral neurotoxicity (CIPN). The review explores innovative strategies to overcome challenges related to chemotherapy, such as drug resistance and side effects, highlighting recent developments in the field, such as Pt(IV) prodrugs and immunotherapeutic approaches to enhance efficacy while minimizing toxicity. Additionally, this manuscript examines experimental models for drug screening, emphasizing the role of murine models and advanced 3D in vitro systems in CRC research. Overall, the review advocates for a comprehensive approach, integrating prevention, early detection, and personalized treatments to alleviate the global burden of CRC.
Oxaliplatin(iv) prodrugs, classified by the role of their axial ligands, are presented with a focus on their in vitro stability and activity in in vivo models, illustrating their potential to address current Pt-based chemotherapy's main limitations.
Reactive oxygen species (ROS) are produced by every aerobic cell during mitochondrial oxidative metabolism as well as in cellular response to xenobiotics, cytokines, and bacterial invasion. Superoxide Dismutases (SOD) are antioxidant proteins that convert superoxide anions (O2•−) to hydrogen peroxide (H2O2) and dioxygen. Using the differential in the level of oxidative stress between normal and cancer cells, SOD mimetics can show an antitumoral effect and prevent oxaliplatin-induced peripheral neuropathy. New Pt(IV) conjugate prodrugs (OxPt-x-Mn1C1A (x = 1, 1-OH, 2)), combining oxaliplatin and a Mn SOD mimic (MnSODm Mn1C1A) with a covalent link, were designed. Their stability in buffer and in the presence of sodium ascorbate was studied. In vitro, their antitumoral activity was assessed by the viability and ROS production of tumor cell lines (CT16, HCT 116, KC) and fibroblasts (primary culture and NIH 3T3). In vivo, a murine model of colorectal cancer was created with subcutaneous injection of CT26 cells in Balb/c mice. Tumor size and volume were measured weekly in four groups: vehicle, oxaliplatin, and oxaliplatin associated with MnSODm Mn1C1A and the bis-conjugate OxPt-2-Mn1C1A. Oxaliplatin-induced peripheral neuropathy (OIPN) was assessed using a Von Frey test reflecting chronic hypoalgesia. Tolerance to treatment was assessed with a clinical score including four items: weight loss, weariness, alopecia, and diarrhea. In vitro, Mn1C1A associated with oxaliplatin and Pt(IV) conjugates treatment induced significantly higher production of H2O2 in all cell lines and showed a significant improvement of the antitumoral efficacy compared to oxaliplatin alone. In vivo, the association of Mn1C1A to oxaliplatin did not decrease its antitumoral activity, while OxPt-2-Mn1C1A had lower antitumoral activity than oxaliplatin alone. Mn1C1A associated with oxaliplatin significantly decreased OIPN and also improved global clinical tolerance of oxaliplatin. A neuroprotective effect was observed, associated with a significantly improved tolerance to oxaliplatin without impairing its antitumoral activity.
As FDA‐approved platinum (Pt) anticancer drugs (e.g. cisplatin, oxaliplatin and carboplatin) grapple with clinical challenges including chemoresistance and systemic side‐effects, Pt(IV) prodrugs have emerged as potent alternative chemotherapies. In this work, a novel bimetallic dual‐action Pt(IV) prodrug bearing a manganese (Mn) superoxide dismutase mimic (SODm) is presented, demonstrating high stability in solution. The prodrug displays intrinsic antisuperoxide properties and in vitro comparable cytotoxic activities to that of oxaliplatin in 2‐ and 3D colorectal cancer cellular models, as well as an increase in intracellular reactive oxygen species (ROS) production. The prodrug is further evaluated in an in vivo mice model for colorectal cancer, demonstrating a similar performance to that of oxaliplatin. Additionally, a total tumor remission is reached with a PEGylated micellar encapsulation of the prodrug. This novel formulation increases the lifetime of the prodrug and therefore its tumoral uptake and plasma content with respect to the unencapsulated drug. This enhanced activity suggests the therapeutic potential of said formulation.
Platinum (Pt)-based chemotherapy has served for decades as the foundation of ovarian cancer therapy. Yet, its gains are always undermined by severe toxic side effects and drug resistance. Although a new generation of therapy - including anti-angiogenic drugs, PARP inhibitors, ADCs, and immune checkpoint inhibitors- has emerged, issues of costs and patient stratification have limited their use as first line treatment. Hence, platinum-based drugs won't be easily surpassed by newer modalities in the immediate future, providing a window of opportunities to make them work more efficiently. This review re-evaluates the future of platinum therapies by exploring key strategies to counteract resistance mediated by intracellular mechanisms and the complex tumour microenvironment. One approach includes converting non-specific and reactive FDA-approved Pt(II) agents into the next-generation Pt(IV) prodrugs, which are stable, single/dual/multi-action or stimuli-triggered agents that become activated only inside target cells, releasing their original Pt(II) counterparts and two additional axial ligands. A second approach includes the development of advanced nanoscale delivery systems to enhance the amount of chemotherapeutic reaching the tumour site while minimizing off target effects. These nanotechnology platforms span from liposomes to virus-like particles and can be engineered to bypass biological obstacles while avoiding premature elimination from the body, even though they are associated with immunogenic reactions. By uniting advances in platinum chemistry with the precision offered by modern nanotechnology, a new therapeutic paradigm emerges-one that can enhance efficacy, reduce systemic toxicity, and offer a more accessible alternative to costly biologics, thereby securing a renewed and enduring role for platinum in ovarian cancer treatment.
17 October 2025 in JBIC Journal of Biological Inorganic Chemistry